We recently published our article Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years. In this article, we discuss Eli Lilly and Company (NYSE:LLY) as one of the stocks gaining attention, and here’s a closer look at why it stands out in today’s market.
The stock market has a funny way of testing investors’ patience. Just when Wall Street starts worrying that the artificial intelligence trade may be getting crowded, stretched, or simply too obvious, another earnings report comes out and reminds everyone why the bullish crowd has not disappeared. That was the broader message from veteran market watcher Ed Yardeni, President of Yardeni Research, when he appeared on CNBC Television on June 26 to discuss the current state of the market, corporate earnings, artificial intelligence spending, and why some of the best stocks to buy now may still have room to run over the next three years.
Yardeni has been one of the more visible bullish voices in the market, and his argument has not been built on hype alone. Instead, he has repeatedly pointed to what he calls “FEMO,” or Fabulous Earnings Momentum. It is a catchy phrase, but behind it is a serious market idea: stocks tend to perform well when earnings continue to surprise on the upside, profit margins remain durable, and corporate America keeps finding ways to grow even in a higher-rate, more selective investment environment. For investors searching for the best long-term stocks, growth stocks to buy, high-upside stocks, artificial intelligence stocks, technology stocks, and stocks that could make investors rich over the next three years, that earnings momentum matters more than short-term market noise.
The current market is not exactly quiet. Investors are still debating interest rates, inflation, valuation, recession risk, Federal Reserve policy, and whether the AI boom is becoming too expensive. But Yardeni’s point is that the market’s foundation remains stronger than many bears expected. Earnings have held up. Big technology companies continue to spend aggressively. Demand tied to artificial intelligence infrastructure remains alive. And even when parts of the market look slow, the weakness may not be a sign of collapse. It may simply be the market catching its breath after a powerful AI-driven rally.
The Market Is Tired of AI Talk, But Not AI Spending
One of the most interesting parts of Yardeni’s CNBC appearance was his discussion of what he described as AI fatigue. Investors have heard the same artificial intelligence story for months: more chips, more servers, more data centers, more cloud computing, more power demand, and more capital expenditure from hyperscalers. At some point, even a strong story can begin to feel overused. That is exactly why some traders have become more cautious toward AI stocks and mega-cap technology stocks, even though the underlying demand picture remains strong.
That is where Micron’s earnings came in as a useful reminder. Yardeni highlighted Micron’s results as evidence that AI hardware demand is still real. The point is simple: artificial intelligence is not just a software story. It is also a hardware, memory, semiconductor, cloud infrastructure, data center, electricity, cooling, and networking story. Every AI model that becomes more powerful requires more computing capacity. Every company that wants to compete in generative AI needs access to better infrastructure. Every hyperscaler that wants to stay ahead must keep building. That is why semiconductor stocks, data center stocks, cloud computing stocks, and AI infrastructure stocks continue to attract attention from long-term investors.
There is also a trivia-like angle here that many casual investors miss. The AI boom is not only about the companies with the most famous chatbots or the most popular consumer-facing applications. Some of the biggest winners in major technology cycles have often been the “picks and shovels” companies, or the firms that provide the infrastructure behind the boom. During the gold rush, not everyone found gold, but the businesses selling tools, transport, and supplies often made consistent money. In the AI era, that same logic applies to chipmakers, memory suppliers, cloud platforms, equipment companies, power infrastructure firms, and the hyperscalers building the digital factories of the future.
Why Hyperscaler Spending Has Become the Market’s Big Question
A major concern among investors is whether hyperscalers are raising and spending too much money on artificial intelligence capital expenditure. The worry is understandable. Data centers are expensive. Advanced chips are expensive. Power supply is expensive. Talent is expensive. The entire AI race requires enormous upfront investment before the full profit opportunity becomes clear. For some investors, that raises a serious question: are the biggest technology companies building the next great profit engine, or are they overspending into a bubble?
Yardeni’s answer leaned toward patience. He noted that many of these hyperscalers are not speculative start-ups with weak balance sheets. They are well-established companies with strong fundamentals, deep cash flows, experienced management teams, and proven business models. In other words, the companies spending heavily on AI are often the same companies that already dominate cloud computing, digital advertising, enterprise software, e-commerce, mobile ecosystems, and online services. That does not remove risk, but it does make the AI capital expenditure story different from a typical market mania funded only by hope.
This is important for anyone looking for stocks with strong upside potential over the next three years. If the hyperscalers are right, today’s aggressive data center spending could become tomorrow’s profit machine. If they are wrong, the market may punish companies that invested too much too quickly. The more balanced view is that investors do not need to assume every AI project will become a massive success. They only need to recognize that the companies with the strongest balance sheets, largest customer bases, and deepest infrastructure advantages may be better positioned to turn AI investment into long-term earnings growth.
Earnings Momentum Is Still the Main Character
For all the excitement around artificial intelligence, the real market driver remains earnings. That is why Yardeni’s FEMO thesis deserves attention. Stock prices can move on headlines in the short term, but over longer periods, earnings growth usually does the heavy lifting. The best stocks to buy and hold are often companies that can grow revenue, protect margins, reinvest capital wisely, and expand profits faster than the broader market expects.
That is also why investors continue to search for high-growth stocks, undervalued stocks, Wall Street analyst picks, hedge fund favorite stocks, and long-term stock market winners. A company does not need to be perfect to become a strong investment. It needs a clear growth path, durable demand, credible management, and enough earnings power to justify a higher valuation over time. In a market driven by both AI optimism and earnings discipline, the best opportunities may come from companies that sit at the intersection of innovation and financial strength.
Another interesting trivia point is that market leadership often changes quietly before most investors notice. The stocks that dominate one cycle are not always the same stocks that lead the next one. In the early days of the internet, many investors focused only on the most obvious names. Later, the winners included companies that built platforms, controlled distribution, scaled infrastructure, or monetized user behavior better than competitors. The AI cycle may follow a similar pattern. Some winners may come from familiar mega-cap technology names, while others may emerge from semiconductors, enterprise software, cybersecurity, energy infrastructure, healthcare technology, financial technology, or industrial automation.
Why the Next Three Years Could Matter for Investors
A three-year investing window is long enough for a powerful business trend to show real results, but short enough for market expectations to change quickly. That is why the idea of “10 stocks that could make investors rich over the next three years” is compelling. It speaks to a very specific kind of opportunity: companies that may not simply perform well, but could potentially outperform the broader market if their earnings, business models, and industry tailwinds continue to improve.
Of course, no serious investor should believe that any stock is guaranteed to make anyone rich. Markets do not work that way. Even the best stocks face risks, including valuation pressure, earnings misses, competition, regulatory issues, interest rate changes, and sudden shifts in investor sentiment. But history also shows that some of the biggest stock market winners are born during periods of doubt. When investors are nervous about spending, valuation, or whether a trend is overhyped, that is often when the strongest companies separate themselves from the rest.
For growth investors, the next three years may be shaped by several major themes: artificial intelligence adoption, data center expansion, semiconductor demand, cloud computing growth, digital transformation, automation, healthcare innovation, defense technology, energy transition, and the continued rise of companies with scalable business models. For value investors, the opportunity may come from high-quality companies that remain overlooked because the market is too focused on the biggest AI names. For long-term investors, the key is not simply finding popular stocks, but identifying companies with the earnings power and competitive advantages to survive market volatility and compound over time.
CHECK THIS OUT: 10 Most Profitable Energy Stocks to Buy in 2026 andTop 10 Stocks That Could Explode 100%.
Our Methodology
To come up with our ranking for the top 10 stocks that could make you a millionaire over the next 3 years, we reviewed reputable financial media lists, identified the stocks most frequently highlighted for long-term upside potential, and ranked them based on hedge fund ownership data and overall institutional interest.
Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years
8. Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE:LLY) lands at No. 8 on this list of the Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years, and this is one of the clearest examples of how healthcare innovation can turn into serious stock market power. Trading at $1,206.51, with the stock up 6.99%, Eli Lilly and Company (NYSE:LLY) has become one of the most dominant pharmaceutical stocks in the market. The company is backed by 132 hedge fund holders, showing that major investors continue to track its long-term growth story. Over the past 30 days, Eli Lilly and Company (NYSE:LLY) has gained roughly 6%, and Wall Street still sees more than 13.6% upside from current levels. For investors searching for healthcare stocks to buy, pharmaceutical stocks, obesity drug stocks, weight loss drug stocks, diabetes treatment stocks, cardiometabolic stocks, and long-term growth stocks, Eli Lilly and Company (NYSE:LLY) remains one of the most powerful names in the market.
The recent optimism around Eli Lilly and Company (NYSE:LLY) was supported by analyst action. On June 25, Leerink analyst David Risinger raised the firm’s price target on Eli Lilly and Company (NYSE:LLY) from $1,119 to $1,232 while maintaining an Outperform rating. Just a few days earlier, on June 22, Berenberg analyst Kerry Holford raised the firm’s price target on Eli Lilly and Company (NYSE:LLY) from $1,050 to $1,135 while keeping a Hold rating on the shares. These price target increases reflect the market’s confidence in the company’s growth engine, especially as demand remains strong for metabolic treatments Mounjaro and Zepbound. Those two drugs have helped turn Eli Lilly and Company (NYSE:LLY) into one of the biggest winners in the global pharmaceutical sector, as obesity and diabetes treatment continue to represent enormous addressable markets.
The trivia behind Eli Lilly and Company (NYSE:LLY) is that its current success is not just about one drug or one trend. The company has spent years building a deep pipeline across cardiometabolic health, oncology, immunology, and neuroscience. Its move into sleep medicine is now attracting fresh attention after the company announced on June 24 that it had completed the acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on developing a new class of medicines for narcolepsy and other sleep-wake disorders. Following the announcement, Eli Lilly and Company (NYSE:LLY) stock gained roughly 1.5%, a sign that investors viewed the transaction as another step in the company’s long-term expansion strategy. Management said Centessa’s work focuses on orexin receptor 2 agonists, which target the orexin system in the brain that helps control wakefulness, alertness, and sleep stability. That may sound technical, but the business point is clear: Eli Lilly and Company (NYSE:LLY) is using its financial strength to broaden its pipeline beyond its already successful metabolic franchise.
This is why Eli Lilly and Company (NYSE:LLY) remains one of the most interesting stocks to watch over the next three years. The company is already a leader in some of the most commercially attractive categories in healthcare, but it continues to push into new areas where demand could expand over time. Its success with Mounjaro and Zepbound has created a massive earnings growth story, while its acquisition activity signals that management is thinking beyond the current product cycle. For investors looking for millionaire-maker stocks, high-growth healthcare stocks, and strong pharmaceutical companies with durable demand, Eli Lilly and Company (NYSE:LLY) offers a rare combination of brand strength, pipeline depth, global scale, and pricing power.
Eli Lilly and Company (NYSE:LLY) develops human pharmaceutical products across cardiometabolic health, oncology, immunology, and other major treatment categories. While valuation remains a real concern because the stock has already delivered strong gains, the company’s growth profile is still one of the strongest in the healthcare sector. If demand for its obesity and diabetes treatments remains strong and its pipeline continues to deliver, Eli Lilly and Company (NYSE:LLY) could remain a core holding for investors seeking exposure to the future of medicine.
YOU MUST READ THIS: Top 10 Cheap Stocks Under $10 To Buy Now
Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.
